类风湿关节炎20年结局:早期治疗与死亡及残疾的关联
基于Norfolk关节炎登记(NOAR)1990—1994年入组、基线符合2010年ACR/EULAR类风湿关节炎(RA)标准的602例患者,随访20年。早期治疗(症状出现≤6个月内)与晚期治疗组死亡风险均低于未治疗组;早期治疗组残疾(HAQ DI)与未治疗组相当,而晚期治疗组HAQ DI升高。
要点
- 早期治疗与较低死亡风险相关,晚期治疗亦优于未治疗
- 早期治疗组20年残疾水平与未治疗组相当
- 晚期治疗组较未治疗组HAQ DI升高,提示延迟治疗与残疾相关
核心结论
- 早期使用改善病情抗风湿药/激素治疗对RA患者长期结局具有重要性。
研究设计与样本
- 基于Norfolk关节炎登记(NOAR)1990—1994年入组患者的起始队列分析,纳入基线符合2010年ACR/EULAR RA标准者602例(中位年龄56岁,四分位距44-68岁;65.9%女性)。
主要发现
- 随访期间肿胀关节数与压痛关节数中位数较低(分别为1-3个和3-6个)。
- HAQ DI中位评分在第1年后升高,但维持低/中等水平(第10年后中位1.25)。
- 与未治疗组相比,早期治疗组和晚期治疗组死亡风险均降低。
- 早期治疗组与未治疗组随访期HAQ DI相当(β=0.03,95%CI -0.06,0.12)。
- 晚期治疗组较未治疗组HAQ DI升高(β=0.10,95%CI 0.02,0.17)。
关键数值与推荐
- 早期治疗定义为症状出现后≤6个月内接受治疗;晚期治疗为>6个月;未治疗为未接受治疗。
- 死亡与残疾关联分别采用加权合并logistic回归和加权多水平混合效应线性回归评估,并以逆权重校正适应证混杂与删失。
临床怎么用
- 对RA患者应尽早(症状出现6个月内)启动改善病情抗风湿药/激素治疗以改善长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the outcome in patients with rheumatoid arthritis (RA) over 20 years from symptom onset, and to assess the association between early treatment (with disease-modifying antirheumatic drugs/steroids) and mortality and disability during follow-up. METHODS: Patients recruited to the Norfolk Arthritis Register (NOAR) between 1990 and 1994 who met the 2010 American College of Rheumatology/European League Against Rheumatism RA criteria at baseline were included in this analysis. Demographic and clinical variables were collected at baseline and at years 1-3, 5, 7, 10, 15, and 20. Disease activity (swollen joint count [SJC]/tender joint count [TJC]), disability (Health Assessment Questionnaire disability index [HAQ DI]), and mortality over 20 years were determined. Associations between treatment group (early treatment [ET], treatment ≤6 months after symptom onset; late treatment [LT], treatment >6 months after symptom onset; never treatment [NT], no treatment) and mortality and disability were assessed using weighted pooled logistic regression and weighted multilevel mixed-effects linear regression, respectively. Inverse weights were used to account for confounding by indication and censoring. RESULTS: This study included 602 patients with RA (median age 56 years [interquartile range 44-68 years]; 65.9% women). The median SJCs and TJCs were low during the follow-up period (1-3 swollen joints and 3-6 tender joints). The median HAQ DI score increased after year 1 but remained at low/moderate levels (median 1.25 after year 10). The risk of mortality was reduced in the ET and LT groups compared with that in the NT group. The ET group and the NT group had comparable HAQ DI scores during the follow-up period (β = 0.03, 95% confidence interval [95% CI] -0.06, 0.12), while the HAQ DI score was increased in the LT group (for LT versus NT, β = 0.10 [95% CI 0.02, 0.17]). CONCLUSION: The results of this study indicate the importance of early treatment with regard to the long-term outcomes in patients with RA.
引用
- Gwinnutt JM, Symmons DPM, MacGregor AJ, et al. Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register. Arthritis Rheumatol. 2017. PMID: 28425173. doi:10.1002/art.40090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。